^
Association details:
| Biomarker: | FOLR1 expression |
|---|---|
| Cancer: | Ovarian Cancer |
| Drug: | AZD5335 (Topoisomerase I inhibitor, Folate receptor 1-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
LB025 / 17 - First disclosure of AZD5335, a TOP1i-ADC targeting low and high FRα-expressing ovarian cancer with superior preclinical activity vs FRα-MTI ADC
Published date:
03/15/2023
Excerpt:
Here, we report that a single dose of AZD5335 at 2.5 mg/kg was sufficient to provide a robust and durable anti-tumor response in FRα-expressing ovarian cancer cell line xenografts (CDX) with a tumor growth inhibition (TGI) of 75%-94% and median best tumor volume reduction >30% in 14/17 (82%) ovarian cancer patient-derived xenografts (PDX) evaluated....These data indicate that AZD5335 is a promising therapeutic candidate for the treatment of ovarian cancers across the spectrum of FRα-expression.
